| Identification | Back Directory | [Name]
Mutated EGFR-IN-1 | [CAS]
1421372-66-8 | [Synonyms]
OMT-3
CS-1173
HY-78869
AZD9291 3
AZD9291 N-2
AZD9291 int-5
AZD9291 INT1 N-2
Mutated EGFR-IN-1
AZD9291DA HCl salt
AZD91 intermediate
Osimertinib analog
AZD9291 intermediate
AZD9291 Intermediate1
Osimertinib Impurity 5
AZD9291 intermediate 4
AZD9291 intermediates 3
Mutated EGFR inhibitor 1
Osimertinib intermediate
Mereletinib Intermediates
Osimertinib Intermediate 3
Mutated EGFR-IN-1 (Osimertinib analog)
N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)b
N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-m-ethyl-1H-indol-3-yl)-2-pyrimidi-nyl]-1,2,
N1-(2-dimethylaminoethyl)-5-methoxy-N1-methyl-N4-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]benzene-1,2,4-triamine
N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-1,2,4-benzenetriamine
1,2,4-Benzenetriamine, N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-
N-(2-dimethylamino-ethyl)-2-methoxy-n-methyl-n-[4-(1-methyl-1h-indol-3-yl)-pyrimidin-2-yl]-5-Amino-benzene-1,4-diamine | [Molecular Formula]
C25H31N7O | [MDL Number]
MFCD28167800 | [MOL File]
1421372-66-8.mol | [Molecular Weight]
445.56 |
| Chemical Properties | Back Directory | [Boiling point ]
676.5±65.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 75 mg/mL (168.33 mM) | [form ]
Powder | [pka]
9.07±0.28(Predicted) | [Appearance]
Off-white to gray Solid | [InChIKey]
HTNTZPBKKCORTP-UHFFFAOYSA-N | [SMILES]
C1(N(CCN(C)C)C)=CC(OC)=C(NC2=NC=CC(C3C4=C(N(C)C=3)C=CC=C4)=N2)C=C1N |
| Hazard Information | Back Directory | [Uses]
N1-?[2-?(Dimethylamino)?ethyl]?-?5-?methoxy-?N1-?methyl-?N4-?[4-?(1-?methyl-?1H-?indol-?3-?yl)?-?2-?pyrimidinyl]?-?1,?2,?4-?benzenetriamine can be involved as reactant/reagent in "Schizophrenic" self-assembly of dual thermoresponsive block copolymers bearing a zwitterionic and a non-ionic hydrophilic block. | [Synthesis]
Under nitrogen protection, 28.5 g (0.060 mol) of N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine was added to 500 mL of methanol with 2.5 g of palladium carbon catalyst. The reaction was stirred at 25 °C for 4 hours in a hydrogen atmosphere. Upon completion of the reaction, the catalyst was removed by filtration and the filtrate was concentrated to dryness under reduced pressure to afford 26 g of the brown solid product N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-1,2,4-benzenetriamine in 97.3% yield. | [IC 50]
EGFRL858R; EGFRExon 19 deletion/T790M; EGFRT790M | [storage]
Store at -20°C | [References]
[1] Patent: CN107216313, 2017, A. Location in patent: Paragraph 0058; 0059; 0071; 0072
[2] Patent: CN108129342, 2018, A. Location in patent: Paragraph 0054; 0055; 0056
[3] Patent: CN107188888, 2017, A. Location in patent: Paragraph 0067-0069; 0070-0072
[4] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 5, p. 2898 - 2901
[5] Patent: CN107793413, 2018, A. Location in patent: Paragraph 0180; 0181; 0184; 0185 |
|
|